Seattle, WA - September 23, 2024: Dr. Surya Viswanadhapalli and Etira founder Dr Ratna Vadlamudi presented a poster titled “The therapeutic potential of ERX-208, a potent inducer of ER stress, in the treatment of ovarian cancer” at the 15th…
https://etira.life/wp-content/uploads/2024/09/Unknown.jpeg8191276Ilona Margolishttps://etira.life/wp-content/uploads/2023/11/etira-life-logo-home.pngIlona Margolis2024-09-23 10:22:362024-09-24 11:49:29Validation of ERX-208 in Ovarian Cancer
Sydney, Australia – September 4, 2024: The Etira team, led by Founder Dr. Ganesh Raj, and the clinical Contract Research Organization Novotech successfully performed the site initiation visit at the Kinghorn Cancer Center (TKCC) in Sydney…
https://etira.life/wp-content/uploads/2024/09/image.png15682324Ilona Margolishttps://etira.life/wp-content/uploads/2023/11/etira-life-logo-home.pngIlona Margolis2024-09-04 10:06:482024-10-15 12:30:25ERX-315-001 SITE INITIATION VISIT @TKCC
Dallas, TX – August 1, 2024: Etira is pleased to announce the approval of the ERX-315 Phase 1 clinical trial by the Australian Human Research Ethics Committee (HREC). This HREC approval enables the start of the clinical trial titled "A Phase…
https://etira.life/wp-content/uploads/2024/08/shutterstock_700277188_edited.jpeg690812Ilona Margolishttps://etira.life/wp-content/uploads/2023/11/etira-life-logo-home.pngIlona Margolis2024-08-01 11:49:472024-10-15 12:30:01ERX-315 CLINICAL TRIAL APPROVED BY HREC
Melbourne, Australia - July 10, 2024: The expansion of Etira partner Medicines Manufacturing Innovation Centre (MMIC) to the Monash Technology Precinct in Clayton was highlighted in the press. This expansion will enable further opportunities…
https://etira.life/wp-content/uploads/2024/07/shutterstock_125779055-scaled.jpg25602127Ilona Margolishttps://etira.life/wp-content/uploads/2023/11/etira-life-logo-home.pngIlona Margolis2024-07-10 12:16:072024-08-12 13:36:07Etira’s Australian partner MMIC expands
Dallas, TX – June 15, 2024: The laboratory of Etira founder Dr Jung-Mo Ahn presents a comprehensive overview of the oligo-benzamide platform that emulates a-helical peptide segments in proteins and disrupts protein-protein interactions. Herein,…
https://etira.life/wp-content/uploads/2024/06/image.jpeg12641756Ilona Margolishttps://etira.life/wp-content/uploads/2023/11/etira-life-logo-home.pngIlona Margolis2024-06-20 10:43:312024-08-02 11:54:06DECRYPTING THE OLIGO-BENZAMIDE PLATFORM
Dallas, TX – May 14th, 2024: Etira is pleased to announce the submission of the regulatory documents for approval of administration of its breakthrough oncology drug ERX-315 to the Human Research Ethics Committee (HREC) in Australia. This…
https://etira.life/wp-content/uploads/2024/05/Etira-Image-for-Press-Release.jpg5631000Ilona Margolishttps://etira.life/wp-content/uploads/2023/11/etira-life-logo-home.pngIlona Margolis2024-05-15 12:36:582024-09-20 11:13:35ERX-315 SUBMITTED FOR HREC APPROVAL
San Diego, CA. April 10, 2024: Etira founder Dr Ratna Vadlamudi’s laboratory presents comprehensive data on the activity of ERX-208 in ovarian cancer. ERX-208 is active against all four molecular subtypes of ovarian cancer and its activity…
https://etira.life/wp-content/uploads/2024/05/Unknown-scaled.jpeg19202560Ilona Margolishttps://etira.life/wp-content/uploads/2023/11/etira-life-logo-home.pngIlona Margolis2024-04-10 11:35:082024-05-17 11:42:20ERX-208 potency in Ovarian Cancer
Dallas, TX. January 24, 2024: We are pleased to present a manuscript in Cancers from the laboratory of Etira founder Dr. Ratna Vadlamudi. The data presented show that ERX-41 targets LIPA in ovarian cancer and is effective against all 4 subtypes…
https://etira.life/wp-content/uploads/2024/01/image.png8661098Ilona Margolishttps://etira.life/wp-content/uploads/2023/11/etira-life-logo-home.pngIlona Margolis2024-01-24 11:44:062024-02-16 07:09:02Targeting LIPA in ovarian cancer
San Antonio, TX. December 7, 2023: Etira is pleased to present the data with its lead compound ERX-315 that cause catastrophic levels of ER stress, resulting in breast cancer cell death, and that can successfully function against multiple forms…
https://etira.life/wp-content/uploads/2024/02/image-1-scaled.jpeg19202560Ilona Margolishttps://etira.life/wp-content/uploads/2023/11/etira-life-logo-home.pngIlona Margolis2023-12-07 11:10:162024-02-13 11:43:07ERX-315 introduced at SABCS 2023
Dallas, TX. October 2, 2023: Etira is pleased to note the independent validation of LIPA as a molecular target in TNBC in a preprint in biorxiv from Dr. Esser’s group in Dusseldorf, Germany.
The authors conclude that LIPA-activity is a novel…
https://etira.life/wp-content/uploads/2023/10/image.png5901000Ilona Margolishttps://etira.life/wp-content/uploads/2023/11/etira-life-logo-home.pngIlona Margolis2023-10-02 11:48:592024-02-16 07:04:35Independent validation of LIPA as a molecular target in TNBC
Patients must be at least 18 years of age at the time of signing the informed consent.
Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1.
Patients must have histologically or cytologically confirmed solid tumor, primarily including but not limited to breast, ovarian, pancreatic, endometrial, and hepatocellular carcinoma, that is advanced unresectable and/or metastatic disease for whom standard therapies do not exist or are no longer effective
Patients must have measurable disease as per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1.
Adequate baseline organ function and hematologic function
Life expectancy >3 months
Exclusion criteria
Systemic anti-cancer therapy within 4 weeks of first dose of study drug
Major surgery (as defined by the Investigator) within 4 weeks of first dose of study drug.
Uncontrolled intercurrent illnesses
Known history of LIPA deficiency, such as Wolman disease or Cholesterol ester storage disease.
Validation of ERX-208 in Ovarian Cancer
NewsERX-315-001 SITE INITIATION VISIT @TKCC
NewsERX-315 CLINICAL TRIAL APPROVED BY HREC
NewsEtira’s Australian partner MMIC expands
NewsDECRYPTING THE OLIGO-BENZAMIDE PLATFORM
NewsERX-315 SUBMITTED FOR HREC APPROVAL
NewsERX-208 potency in Ovarian Cancer
NewsTargeting LIPA in ovarian cancer
NewsERX-315 introduced at SABCS 2023
NewsIndependent validation of LIPA as a molecular target in TNBC
News